Ross A Miller

US Patent:

6369247, Apr 9, 2002

Filed:

Sep 30, 1996

Appl. No.:

08/718408

Inventors:

Ross A. Miller - Fanwood NJ
Andrew S. Thompson - Mountainside NJ
Raman K. Bakshi - Edison NJ
Edward G. Corley - Old Bridge NJ

Assignee:

Merck Co., Inc. - Rahway NJ

International Classification:

C07J 900

US Classification:

552542, 552636, 540 2, 540106

Abstract:

The instant invention involves a process for oxidizing compounds containing an allylic group, i. e. those containing an allylic hydrogen or allylic alcohol group, to the corresponding enones, using a ruthenium-based catalyst in the presence of a hydroperoxide. Particularly, -5-steroidal alkenes can be oxidized to the corresponding -5-7-keto alkenes.

US Patent:

7863307, Jan 4, 2011

Filed:

Jun 29, 2006

Appl. No.:

11/922905

Inventors:

Ross A. Miller - Rahway NJ, US
Aaron S. Cote - Rahway NJ, US

International Classification:

A61K 31/421
C07D 263/20

US Classification:

514376, 548229

Abstract:

An efficient process is disclosed for producing a compound that is an inhibitor of CETP. The last step of the process is the coupling of an oxazolidinone derivative with a biphenyl moiety to provide a compound of formula (I). In a specific embodiment of this synthesis, a crystalline product is produced which is characterized as a non-solvated crystalline polymorph.

US Patent:

20030191121, Oct 9, 2003

Filed:

Aug 6, 2002

Appl. No.:

10/212978

Inventors:

Ross Miller - Fanwood NJ, US
Sandor Karady - Mountainside NJ, US
Paul Reider - Westfield NJ, US

International Classification:

A61K031/541
A61K031/5377
A61K031/498
C07D487/02

US Classification:

514/228500, 514/234200, 514/249000, 544/060000, 544/117000, 544/350000

Abstract:

Piperazine carboxamide intermediates of HIV protease inhibitors and a process for their preparation are disclosed. The piperazine carboxamide compounds are of Formula (III): wherein R, R, R, R, R, and Rare defined herein. The process for preparing the intermediates comprises coupling an iminium salt of Formula I: with a metallated derivative of a compound of Formula (II): wherein L is a counterion. A process for preparing the iminium salt of Formula (I) is also disclosed, as is a process for preparing HIV protease inhibitors from Compound III.

US Patent:

20040147787, Jul 29, 2004

Filed:

Jan 5, 2004

Appl. No.:

10/482941

Inventors:

Ross Miller - Fanwood NJ, US

International Classification:

C07D207/46
C07C045/27

US Classification:

568/428000, 548/571000

Abstract:

The use of iodine as a primary oxidant for TEMPO provides a novel and selective method for oxidizing alcohols to their corresponding carbonyl compounds.

US Patent:

55853838, Dec 17, 1996

Filed:

May 3, 1995

Appl. No.:

8/434082

Inventors:

Andrew L. Forman - Scotch Plains NJ
Sean R. Holihan - Dayton NJ
Guy R. Humphrey - Belle Mead NJ
David M. Lashen - Edison NJ
James A. McCauley - Belle Mead NJ
Paul F. McKenzie - Yardley PA
Ross A. Miller - Fanwood NJ
Pascal H. Toma - Piscataway NJ

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C07S 7300
A61K 3158

US Classification:

514284

Abstract:

By this invention, there is provided a process for producing crystalline 4,7. beta. -dimethyl-4-aza-5. alpha. -cholestan-3-one of structural formula (I) from 4,7. beta. -dimethyl-4-aza-5. alpha. -cholestan-3-one oil. ##STR1## This crystallization process of the present invention comprises crystallization of the oil optionally containing residual solvent with vigorous but controlled agitation. Preferably, this crystallization process is carried out at select and controlled temperatures. Further, 4,7. beta. -dimethyl-4-aza-5. alpha. -cholestan-3-one has been found to exist in at least two novel polymorphic nonsolvated forms, herein referred to as Form I and Form II. Form I can be prepared pure by careful control of the crystallization process.

US Patent:

62520636, Jun 26, 2001

Filed:

Nov 2, 1999

Appl. No.:

9/432864

Inventors:

Ross A. Miller - Fanwood NJ
Scott S. Ceglia - Woodbridge NJ

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A61K 314995
C07D47708
C07D47714

US Classification:

540302

Abstract:

Crystalline salts of an amorphous, unstable carbapenem antibiotic having the formula: ##STR1## are disclosed, wherein R. sup. - represents beyslate, tosylate, napsylate, saccharate or alizarate.